Residual vectors for Alzheimer disease diagnosis and prognostication
David Glenn Clark, Alzheimer Disease Neuroimaging Initiative, David Glenn Clark, Alzheimer Disease Neuroimaging Initiative
Abstract
Alzheimer disease (AD) is an increasingly prevalent neurodegenerative condition and a looming socioeconomic threat. A biomarker for the disease could make the process of diagnosis easier and more accurate, and accelerate drug discovery. The current work describes a method for scoring brain images that is inspired by fundamental principles from information retrieval (IR), a branch of computer science that includes the development of Internet search engines. For this research, a dataset of 254 baseline 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) scans was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI). For a given contrast, a subset of scans (nine of every 10) was used to compute a residual vector that typified the difference, at each voxel, between the two groups being contrasted. Scans that were not used for computing the residual vector (the remaining one of 10 scans) were then compared to the residual vector using a cosine similarity metric. This process was repeated sequentially, each time generating cosine similarity scores on 10% of the FDG-PET scans for each contrast. Statistical analysis revealed that the scores were significant predictors of functional decline as measured by the Functional Activities Questionnaire (FAQ). When logistic regression models that incorporated these scores were evaluated with leave-one-out cross-validation, cognitively normal controls were discerned from AD with sensitivity and specificity of 94.4% and 84.8%, respectively. Patients who converted from mild cognitive impairment (MCI) to AD were discerned from MCI nonconverters with sensitivity and specificity of 89.7% and 62.9%, respectively, when FAQ scores were brought into the model. Residual vectors are easy to compute and provide a simple method for scoring the similarity between an FDG-PET scan and sets of examples from a given diagnostic group. The method is readily generalizable to any imaging modality. Further interdisciplinary work between IR and clinical neuroscience is warranted.
Figures
References
- Casey MA, Veltkamp R, Goto M, Leman M, Rhodes C, Slaney M. Content-based information retrieval: current directions and future challenges. Proc. IEEE. 2008;96:668–696.
- Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374–1377.
- Cuingnet R, Gerardin E, Tessieras J, Auzias G, Lehericy S, Habert M-O, et al. Automatic classification of patients with Alzheimer's disease from structural MRI: A comparison of ten methods using the ADNI database. NeuroImage. 2010;56:766–781.
- Datta R, Joshi D, Li J, Wang JZ. Image retrieval: ideas, influences, and trends of the new age. ACM Comput. Surv. 2008;40:5:1–5:60.
- Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulos P, Minoshima S, Schwaiger M, Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J. Nucl. Med. 2005;46:1625–1632.
- Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6:501–512.
- Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616–2635.
- Greicius MD, Srivastava G, Reiss A, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. 2004;101:4637–4642.
- Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb. Cortex. 2008;19:72–78.
- Hebert LE, Scherr PA, Bienias JL, Bennet DA, Evans DA. Alzheimer Disease in the US population. Prevalence estimates using the 2000 census. Arch. Neurol. 2003;60:1119–1122.
- Landau SM, Harvey D, Madison CM, Koeppe RA, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging. 2011;32(7):1207–1218.
- Landau SM, Harvey D, Madison CM, Reiman EM. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230–238.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944.
- Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 1995;36:1238–1248.
- Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ. 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J. Nucl. Med. 2007;48:1129–1134.
- Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med. 2005;352:2379–2385.
- Raichle M, MacLeod A, Snyder A, Powers W, Gusnard D, Shulman G. A default mode for brain function. Proc. Natl. Acad. Sci. 2001;98:676–682.
- R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
- Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment. Neurology. 2004;63:651–657.
- Silverman DH, Small GW, Chang CY, Lu CS, Kung de Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia. Regional brain metabolism and long-term outcome. J Am. Med. Assoc. 2001;286:2120–2127.
- Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204–1215.
- Walhovd KB, Fjell AM, Brewer J, McEvoy LK. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am. J. Neurorad. 2010;31:347–354.
- Widdows D, Peters S. Word vectors and quantum logic: experiments with negation and dysjunction. Proceedings of Mathematics of Language. 2003;8:141–154.
- Widdows D. Geometry and meaning. Stanford, CA: CSLI; 2004.
- Woods RP, Grafton S, Holmes C, Cherry S, Mazziotta JC. Automated image registration: I. General methods and intrasubject, intramodality validation. J. Comput. Assist. Tomogra. 1998;22:139–152.
Source: PubMed